Sponsored By
A Big Three Months for Biotech ETFsA Big Three Months for Biotech ETFs
Biotech-focused ETFs dominated the list of the 20 top-performing funds over the past three months.
21 Slides

Already have an account?
JaysonPhotography/iStock/Getty Images Plus
Based on three-month returns. Minimum of $5 million in net assets, excluding leveraged and inverse ETFs.
Data as of 12/2/2019.
Aniket Ullal is the founder and CEO of First Bridge Data, a provider of independent ETF data and analytics to institutional clients. Previously he had product management responsibility for S&P’s U.S. indexes, including the widely followed S&P 500 and S&P/Case-Shiller indexes. He is the author of ETF Investment Strategies (McGraw-Hill, 2013).
About the Author
You May Also Like